SCHEMBL7901967

SCHEMBL7901967

C[C@H](NC(=O)C1(c2ccc(F)cc2)CCNCC1)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.43
KCNH2 Q12809 1/20 0.41
CACNA1I Q9P0X4 1/20 0.41
AVPR1A P37288 4/20 0.41
ALDH1A1 P00352 2/20 0.41
OPRL1 P41146 1/20 0.40
OXTR P30559 1/20 0.40
CTSL P07711 1/20 0.39
IDO1 P14902 2/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
MMP2 P08253 2/20 0.37
CA9 Q16790 2/20 0.37
HDAC1 Q13547 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
P2RX7 Q99572 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102668 1.00 MAPK1 (0.43) MAPK1KCNH2CACNA1IAVPR1AALDH1A1
SCHEMBL13092156 0.88 ALDH1A1 (0.51) KCNH2ALDH1A1OPRL1TAS1R3TAS1R1
SCHEMBL7899606 0.79 HTT (0.48) KCNH2ALDH1A1NPC1
SCHEMBL6410686 0.79 HDAC4 (0.50) KCNH2AVPR1AALDH1A1OXTRTAS1R3
SCHEMBL6404625 0.79 HDAC4 (0.50) KCNH2AVPR1AALDH1A1OXTRTAS1R3
SCHEMBL13102665 0.79 HTT (0.48) KCNH2ALDH1A1NPC1
SCHEMBL13102753 0.79 EPHX2 (0.46) MAPK1ALDH1A1OPRL1
SCHEMBL378760 0.79 EPHX2 (0.46) MAPK1ALDH1A1OPRL1
SCHEMBL7907628 0.76 NPC1 (0.51) ALDH1A1OPRL1HDAC1NPC1
SCHEMBL13102482 0.76 NPC1 (0.51) ALDH1A1OPRL1HDAC1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 MAPK1 2085/4885KCNH2 104/4885CACNA1I 994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.